gemcitabine has been researched along with pik 75 in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bae, I; Duong, HQ; Hong, YB; Kang, HJ; Seong, YS; Tang, W; Wang, A; Yi, YW | 1 |
1 other study(ies) available for gemcitabine and pik 75
| Article | Year |
|---|---|
Inhibition of NRF2 by PIK-75 augments sensitivity of pancreatic cancer cells to gemcitabine.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Hydrazones; Mice; NF-E2-Related Factor 2; Pancreatic Neoplasms; Sulfonamides; Xenograft Model Antitumor Assays | 2014 |